| Literature DB >> 24779617 |
Marco Rizzi1, Veronica Ravasio, Alessandra Carobbio, Irene Mattucci, Massimo Crapis, Roberto Stellini, Maria Bruna Pasticci, Pierangelo Chinello, Marco Falcone, Paolo Grossi, Francesco Barbaro, Angelo Pan, Pierluigi Viale, Emanuele Durante-Mangoni.
Abstract
BACKGROUND: Embolic events are a major cause of morbidity and mortality in patients with infective endocarditis. We analyzed the database of the prospective cohort study SEI in order to identify factors associated with the occurrence of embolic events and to develop a scoring system for the assessment of the risk of embolism.Entities:
Mesh:
Year: 2014 PMID: 24779617 PMCID: PMC4101861 DOI: 10.1186/1471-2334-14-230
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Demographic and clinical characteristics of the cohort*
| Number of IE episodes | 1456 (100) | 967 (66.4) | 339 (23.3) | 89 (6.1) | 61 (4.2) |
| Age (y) | 65 (50 to 64) | 64 (48 to 74) | 70 (61 to 76) | 48 (35 to 67) | 67 (55 to 77) |
| Male | 1018 (70) | 688 (71) | 221 (65) | 61 (69) | 48 (79) |
| Comorbidity and predisposing conditions | | ||||
| Native valve disease | 372 (26) | 299 (31) | 60 (18) | 7 (8) | 6 (10) |
| Diabetes mellitus | 268 (18) | 164 (17) | 79 (23) | 10 (11) | 15 (25) |
| Chronic liver disease | 262 (18) | 169 (18) | 49 (15) | 38 (43) | 6 (10) |
| Cancer | 175 (12) | 131 (14) | 28 (8) | 10 (11) | 6 (10) |
| Chronic intravenous access | 154 (11) | 102 (11) | 34 (10) | 11 (12) | 7 (12) |
| Current intravenous drug abuse | 131 (9) | 81 (8) | 14 (4) | 34 (38) | 2 (3) |
| Previous IE | 118 (8) | 48 (5) | 59 (17) | 7 (8) | 4 (7) |
| Congenital heart disease | 112 (8) | 85 (9) | 16 (5) | 6 (7) | 5 (8) |
| Immunosuppressive therapy | 86 (6) | 70 (7) | 11 (3) | 2 (2) | 3 (5) |
| HIV infection | 52 (4) | 36 (4) | 4 (1) | 10 (11) | 2 (3) |
| Hemodialysis | 29 (2) | 21 (2) | 4 (1) | 2 (2) | 2 (3) |
| Microbiology | | ||||
| | 283 (19) | 181 (19) | 53 (16) | 35 (39) | 14 (23) |
| Viridans group streptococci | 217 (15) | 172 (18) | 29 (9) | 8 (9) | 8 (13) |
| | 182 (13) | 117 (12) | 53 (16) | 8 (9) | 4 (7) |
| Coagulase-negative staphylococci | 147 (10) | 74 (8) | 55 (16) | 4 (5) | 14 (23) |
| | 142 (10) | 105 (11) | 29 (9) | 7 (8) | 1 (2) |
| Other streptococci | 59 (4) | 46 (5) | 7 (2) | 3 (3) | 3 (5) |
| Other microorganisms | 61 (4) | 36 (4) | 20 (6) | 2 (2) | 3 (5) |
| Polymicrobial | 51 (4) | 34 (4) | 10 (3) | 4 (5) | 3 (5) |
| Fungi | 20 (1) | 12 (1) | 8 (2) | 0 (0) | 0 (0) |
| HACEK | 3 (0.2) | 0 (0) | 2 (0.6) | 1 (1) | 0 (0) |
| Microbiology negative | 291 (20) | 190 (20) | 73 (22) | 17 (19) | 11 (18) |
*Data reported as number, median (interquartile range), or number (% patients).
Abbreviations:CIED-IE infective endocarditis associated with a cardiac implantable electronic device, HACEKHaemophilus species, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae, HIV human immunodeficiency virus, LS-NVE left-sided native valve endocarditis, LS-PVE left-sided prosthetic valve endocarditis, RS-IE right-sided infective endocarditis.
Type and anatomic site of embolic events*
| Number of IE episodes | 1456 | 967 | 339 | 89 | 61 |
| Embolic events | 700 | 436 | 166 | 74 | 24 |
| CNS emboli | 249 (36) | 174 (40) | 68 (41) | 3 (4) | 4 (17) |
| Ischemic stroke | 176 (25) | 126 (29) | 45 (27) | 2 (3) | 3 (13) |
| Transient ischemic attack | 42 (6) | 26 (6) | 14 (8) | 1 (1) | 1 (4) |
| Hemorrhagic stroke | 31 (4) | 22 (5) | 9 (6) | 0 (0) | 0 (0) |
| Peripheral emboli | 451 (64) | 262 (60) | 98 (59) | 71 (96) | 20 (83) |
| Pulmonary | 122 (17) | 26 (6) | 25 (15) | 57 (84) | 14 (58) |
| Splenic | 117 (17) | 90 (21) | 23 (14) | 3 (4) | 1 (4) |
| Limbs | 95 (14) | 70 (16) | 15 (9) | 7 (10) | 3 (13) |
| Other | 117 (17) | 76 (17) | 35 (21) | 4 (6) | 2 (8) |
*Data reported as number or number (% of embolic events).
Abbreviations: CIED-IE infective endocarditis associated with a cardiac implantable electronic device, LS-NVE left-sided native valve endocarditis, LS-PVE left-sided prosthetic valve endocarditis, RS-IE right-sided infective endocarditis.
Figure 1Timing of embolic events. Negative values represent days before the beginning of the antibiotic therapy; zero represents the day of the beginning of antibiotic therapy; positive values represent the days after the beginning of the antibiotic therapy.
Total cohort: univariate analysis of factors associated with embolism*
| | | ||
|---|---|---|---|
| Number of episodes of IE | 499 | 957 | |
| Male | 361 (72) | 657 (69) | NS |
| Hemodialysis | 10 (2) | 19 (2) | NS |
| Diabetes mellitus | 86 (17) | 182 (19) | NS |
| Previous IE | 38 (8) | 80 (8) | NS |
| Chronic intravenous access | 59 (12) | 95 (10) | NS |
| Congenital heart disease | 38 (8) | 74 (8) | NS |
| Native valve predisposition | 132 (26) | 270 (28) | NS |
| Nosocomial IE | 29 (6) | 50 (5) | NS |
| Health care associated IE | 107 (21) | 227 (24) | NS |
| Community-acquired IE | 363 (73) | 680 (71) | NS |
| Native vs prosthetic valve | 385 vs 114 | 732 vs 225 | NS |
| Site of IE (n = 1282) | | ||
| Mitral vs aortic valve | 166 vs 161 | 329 vs 359 | NS |
| Bivalvular involvement (mitral and aortic) | 39 (8) | 78 (8) | NS |
| CIED-IE | 21 (4) | 40 (4) | NS |
| Vegetations (n = 710)‡ | | ||
| | |||
| | |||
| | |||
| | |||
| Concomitant therapy at onset of IE | | ||
| Anticoagulants | 102 (20) | 228 (24) | NS |
| Antiaggregants | 68 (14) | 103 (11) | NS |
| Microbiology | | | |
| | |||
| Viridans group streptococci | 66 (13) | 151 (16) | NS |
| Coagulase-negative staphylococci | 52 (10) | 95 (10) | NS |
| | |||
| | 44 (9) | 98 (10) | NS |
| Polymicrobial | 19 (4) | 32 (3) | NS |
| Other microorganisms | 16 (3) | 45 (6) | NS |
| Other streptococci | 16 (3) | 43 (5) | NS |
| Fungi/yeasts | 7 (1) | 13 (1) | NS |
| HACEK | 1 (0.2) | 2 (0.2) | NS |
| Microbiology negative | 92 (18) | 199 (21) | NS |
*Total cohort, N = 1456 episodes of infective endocarditis. Data reported as number, median (range, 5th to 95th percentile), or number (%). Abbreviations:CIED-IE infective endocarditis associated with a cardiac implantable electronic device, HACEKHaemophilus species, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae, HIV human immunodeficiency virus, IE infective endocarditis.
†NS, not significant (p > 0.05).
‡ IE episodes with vegetations of known size: 710 episodes (290 episodes with embolism and 420 episodes without embolism).
Bold numbers represent statistically significant differences.
Figure 2Total cohort: size of vegetation. Receiver operating characteristic analysis for the prediction of embolic events, based on vegetation size.
Total cohort: multivariate analysis of factors associated with embolism*
| Age | 1.0 | 1.0 – 1.0 | NS |
| HIV infection | 0.8 | 0.3 – 2.0 | NS |
| Cancer | 1.10 | 0.7 – 1.9 | NS |
| Chronic liver disease | 1.4 | 0.9 – 2.2 | NS |
| Mitral vs aortic valve | 1.0 | 0.7 – 1.3 | NS |
| 1.6 | 1.0 – 2.6 | NS | |
| 0.8 | 0.4 – 1.4 | NS | |
| Anticoagulant therapy | 0.8 | 0.5 – 1.3 | NS |
*N = 1456 IE episodes. Abbreviation:HIV human immunodeficiency virus.
†NS, not significant (p > 0.05).
Bold numbers represent statistically significant differences.
Figure 3Left-sided IE: Kaplan-Meier plots of failure rates (embolic events) for different risk categories. Bold numbers: number of patients at risk at any given time. Numbers in parentheses: number of embolic events that occurred in each time interval.
Left-sided IE: 30-day probability (%) of embolic events per risk category
| 0 | 11.78 | 24.54 | 37.73 |
| 1 | 7.90 | 20.82 | 34.79 |
| 2 | 6.61 | 18.95 | 25.97 |
| 3 | 4.88 | 16.13 | 25.97 |
| 4 | 4.01 | 14.70 | 25.97 |
| 5 | 4.01 | 12.78 | 25.97 |
| 6 | 3.14 | 11.34 | 25.97 |
| 7 | 2.71 | 8.95 | 22.81 |
| 15 | 0.48 | 5.02 | 3.46 |
| 30 | 0.00 | 0.00 | 0.00 |
Note: numbers represent the probability (%) of embolism at the end of a given time interval. Time 0 values include embolic events occurred on the first calendar day of therapy; day 1 values represent the risk at the end of the first calendar day of therapy.